Half Year 2025 SKAN Group AG Earnings Call Transcript
Key Points
- SKAN Group AG (XSWX:SKAN) reported a significant increase in order intake, with a 20% growth compared to the previous half-year, driven by demand in the pharmaceutical market.
- The company has a record-high order backlog of CHF386.4 million, providing strong visibility for future sales.
- SKAN Group AG has completed two strategic acquisitions, ABC Transfer and Medtronic, which align with their strategy to expand aftermarket service and digital integration offerings.
- The company continues to invest in strategic initiatives, with CHF21.5 million invested in pre-approved services, maintaining a focus on future growth.
- SKAN Group AG's financial structure remains solid with a net cash position of CHF43 million and an equity ratio of 48.1%, supporting future growth and acquisitions.
- Net sales are 17% behind plan due to project postponements, particularly in vaccine filling lines and a major GLP1 project.
- The EBITDA margin is low, impacted by the missing top line and project delays, resulting in a decline from CHF21 million to CHF0.9 million.
- The company faces challenges with the cyclical and lumpy nature of its business, exacerbated by the accumulation of project postponements.
- There is a risk of further postponements or cancellations of vaccine projects, which could impact future revenue.
- The geopolitical situation and tariffs in the US market pose potential challenges, although SKAN Group AG has strategies in place to mitigate these risks.
I would like to welcome you to the half year figure presentation 2025. You can see the agenda on the screen. I will start with an overview. Burri Maraj, our CFO, will then talk about the financial results more in detail. I will then close with an outlook for the end of 2025 and maybe the upcoming '26 and future, and then we would be happy to answer some questions from you.
Starting with the overview, I think we can positively mention that the order intake has really increased significantly, basically supporting the pharmaceutical market growth or basically the injectable drug market growth with 20% growth versus half year one and actually also versus half year two last year, we are here again on a very good. On a very good level.
At the same time, the order backlog is at a record high of CHF386.4 million. On the net sales side, we are 17% behind the plan. The reason for that is mainly the postponement of projects. We here we see two major reasons. One is that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
